ATE488529T1 - Zusammensetzungen und verfahren zur behandlung von tumoren - Google Patents

Zusammensetzungen und verfahren zur behandlung von tumoren

Info

Publication number
ATE488529T1
ATE488529T1 AT00950879T AT00950879T ATE488529T1 AT E488529 T1 ATE488529 T1 AT E488529T1 AT 00950879 T AT00950879 T AT 00950879T AT 00950879 T AT00950879 T AT 00950879T AT E488529 T1 ATE488529 T1 AT E488529T1
Authority
AT
Austria
Prior art keywords
gene
treatment
methods
diagnosis
compositions
Prior art date
Application number
AT00950879T
Other languages
German (de)
English (en)
Inventor
Sarah Bodary
Karen Fisher
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE488529T1 publication Critical patent/ATE488529T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00950879T 1999-07-28 2000-07-27 Zusammensetzungen und verfahren zur behandlung von tumoren ATE488529T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14621799P 1999-07-28 1999-07-28
PCT/US2000/020731 WO2001009189A2 (en) 1999-07-28 2000-07-27 Compositions and methods for the treatment of tumors

Publications (1)

Publication Number Publication Date
ATE488529T1 true ATE488529T1 (de) 2010-12-15

Family

ID=22516336

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00950879T ATE488529T1 (de) 1999-07-28 2000-07-27 Zusammensetzungen und verfahren zur behandlung von tumoren

Country Status (9)

Country Link
US (2) US7226596B2 (enExample)
EP (1) EP1204682B1 (enExample)
JP (3) JP2003508028A (enExample)
AT (1) ATE488529T1 (enExample)
AU (1) AU776600B2 (enExample)
CA (1) CA2378182C (enExample)
DE (1) DE60045247D1 (enExample)
ES (1) ES2355055T3 (enExample)
WO (1) WO2001009189A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003508028A (ja) * 1999-07-28 2003-03-04 ジェネンテック・インコーポレーテッド 腫瘍治療のための組成物と方法
CA2462133A1 (en) * 2002-02-20 2003-08-28 Kunitake Abe Novel polypeptide
WO2005090991A1 (en) * 2004-03-24 2005-09-29 Oncotherapy Science, Inc. Adam8 as tumor marker and therapeutic target for non-small cell lung cancer
CN1854313B (zh) * 2002-09-30 2010-10-20 肿瘤疗法科学股份有限公司 非小细胞肺癌的诊断方法
US20080014594A1 (en) * 2003-01-31 2008-01-17 Kevin Hestir Lung-Expressed Polypeptides
DE602005011321D1 (de) * 2004-11-10 2009-01-08 Novartis Vaccines & Diagnostic Deamidiertes interferon-beta
FR2879462B1 (fr) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic Utilisation de toxine botulique pour une insensibilisation locale prolongee
EP2290088A1 (en) * 2004-12-22 2011-03-02 Genentech, Inc. Methods for producing soluble multi-menbrane-spanning proteins
US20060242012A1 (en) * 2005-04-22 2006-10-26 Sumit Agarwal Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
US9156914B2 (en) 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
KR101604649B1 (ko) * 2007-11-27 2016-03-18 베리덱스, 엘엘씨 혈액 내 순환 흑색종 세포의 자동화된 계산 및 특징화
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
ES2902420T3 (es) * 2013-05-13 2022-03-28 Univ Tufts Composiciones para el tratamiento del cáncer que expresa ADAM8
TW201613622A (en) * 2014-10-14 2016-04-16 Bionet Corp Composition for skincare and pharmaceutical composition and preparation method thereof
TW201613621A (en) * 2014-10-14 2016-04-16 Bionet Corp Composition for promoting growth of dermal papilla cells, pharmaceutical composition, and preparation method thereof
JP2018130113A (ja) * 2017-02-15 2018-08-23 国立大学法人 東京大学 慢性骨髄性白血病（ｃｍｌ）の検査方法及び検査用キット、チロシンキナーゼ阻害剤（ｔｋｉ）耐性ｃｍｌの単離方法、並びにｃｍｌにおけるｔｋｉ耐性の低減剤及びそのスクリーニング方法
EP3976655A4 (en) 2019-05-31 2023-07-05 Trustees of Tufts College Anti-adam8 antibodies and uses of the same

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04187084A (ja) * 1990-11-22 1992-07-03 Otsuka Pharmaceut Co Ltd 単球表面に発現する抗原及び該抗原に対するモノクローナル抗体
JP3297053B2 (ja) * 1994-01-20 2002-07-02 ブリテッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
GB9608130D0 (en) 1996-04-19 1996-06-26 Univ Sheffield Adam proteins and uses thereof
US6132729A (en) * 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment
GB9705521D0 (en) * 1997-03-18 1997-05-07 Univ Sheffield The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue
US5922566A (en) * 1997-05-13 1999-07-13 Incyte Pharmaceuticals, Inc. Tumor-associated antigen
GB2339200B (en) * 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
WO2000040749A2 (en) * 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
US20010034023A1 (en) * 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
JP2003508028A (ja) * 1999-07-28 2003-03-04 ジェネンテック・インコーポレーテッド 腫瘍治療のための組成物と方法
US7074408B2 (en) * 2000-02-25 2006-07-11 Immunex Corporation Use of integrin antagonists to inhibit angiogenesis
WO2001071027A2 (en) * 2000-03-24 2001-09-27 Micromet Ag mRNA AMPLIFICATION
US6458552B1 (en) * 2000-06-06 2002-10-01 Ortho-Mcneil Pharmaceutical, Inc. Metalloprotease peptide substrates and methods
AU2002213005A1 (en) * 2000-10-02 2002-04-15 Board Of Regents, The University Of Texas System Method of detection and interpretation of mutations through expression or function tests of haploid genes
WO2002048310A2 (en) * 2000-12-15 2002-06-20 Genetics Institute, Llc Methods and compositions for diagnosing and treating rheumatoid arthritis
WO2002085285A2 (en) * 2001-04-18 2002-10-31 Wyeth Methods and reagents for regulating bone and cartilage formation
US20030138792A1 (en) * 2001-05-31 2003-07-24 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
AU2002318944A1 (en) * 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
US20030148334A1 (en) * 2001-10-12 2003-08-07 Zairen Sun Differentially-expressed genes and polypeptides in angiogenesis
MXPA04008286A (es) * 2002-03-01 2005-07-27 Children S Hospital And Region Tratamiento para asma o alergias.
US20040018522A1 (en) * 2002-05-09 2004-01-29 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with multiple sclerosis
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
JP2004041121A (ja) * 2002-07-12 2004-02-12 Hitachi Ltd アレルギー解析方法及びシステム
EP2474630B1 (en) * 2002-12-20 2016-04-27 Celera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
WO2004089294A2 (en) * 2003-04-04 2004-10-21 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
US20050009067A1 (en) * 2003-05-19 2005-01-13 Craig Logsdon Expression profile of pancreatic cancer
US20050059101A1 (en) * 2003-09-10 2005-03-17 Gordon Ringold Bivalent targeting of cell surfaces

Also Published As

Publication number Publication date
US20080175842A1 (en) 2008-07-24
AU776600B2 (en) 2004-09-16
EP1204682B1 (en) 2010-11-17
AU6391300A (en) 2001-02-19
EP1204682A2 (en) 2002-05-15
US7226596B2 (en) 2007-06-05
JP5897300B2 (ja) 2016-03-30
ES2355055T3 (es) 2011-03-22
JP2014144959A (ja) 2014-08-14
JP2012068254A (ja) 2012-04-05
US20030113764A1 (en) 2003-06-19
DE60045247D1 (de) 2010-12-30
JP2003508028A (ja) 2003-03-04
CA2378182A1 (en) 2001-02-08
WO2001009189A3 (en) 2001-06-14
CA2378182C (en) 2014-09-23
WO2001009189A2 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
DE60045247D1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
WO1999035170A8 (en) Compositions and methods for the treatment of tumor
ATE380195T1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
WO1999014327A3 (en) Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer
WO2003032813A3 (en) Methods for the treatment of carcinoma
WO2000053755A3 (en) Compositions and methods for the treatment of tumor
ATE440109T1 (de) Methoden zur diagnose von tumoren
ATE397621T1 (de) Hemmer der interaktion zwischen p53 und mdm2
WO2004075835A3 (en) Methods for the treatment of renal cell carcinoma
WO2000015666A3 (en) Compositions and methods for the treatment of tumors
DE69940681D1 (de) Zusammensetzung und Verfahren zur Diagnose von Tumoren
ATE466938T1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
WO2000037640A3 (en) Compositions and methods for the treatment of tumor
ATE295963T1 (de) Zusammensetzungen sowie verfahren zur diagnose und behandlung von tumorerkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1204682

Country of ref document: EP